The effect of HMG-CoA reductase inhibitors on cognition in patients with alzheimer's dementia: A prospective withdrawal and rechallenge pilot study

American Journal of Geriatric Pharmacotherapy

Volumn 10, Issue 5, 2012, Pages 296-302

  Padala, Kalpana P ^a,b   Padala, Prasad R ^a,b,c   McNeilly, Dennis P ^d   Geske, Jenenne A ^d   Sullivan, Dennis H ^a,b   Potter, Jane F ^e  

^a GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Alzheimer's dementia; cognition; statins

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITION; DAILY LIFE ACTIVITY; DRUG EFFECT; FEMALE; GERIATRIC HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PILOT STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; CHOLESTEROL; COGNITION; COGNITION DISORDERS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84867403473     PISSN: 15435946     EISSN: 18767761     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2012.08.002     Document Type: Article

References (29)

1. W.J. Kostis, J.Q. Cheng, J.M. Dobrzynski Meta-analysis of statin effects in women versus men J Am Coll Cardiol 59 2012 572 582
2. J.C. LaRosa, J. He, S. Vupputuri Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials JAMA 282 1999 2340 2346
3. B. Wolozin, W. Kellman, P. Ruosseau, G.G. Celesia, G. Siegel Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors Arch Neurol 57 2000 1439 1443
4. H. Jick, G.L. Zornberg, S.S. Jick Statins and the risk of dementia Lancet 356 2000 1627 1631
5. K. Rockwood, S. Kirkland, D.B. Hogan Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people Arch Neurol 59 2002 223 227
6. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
7. J. Shepherd, G.J. Blauw, M.B. Murphy Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
8. H.H. Feldman, R.S. Doody, M. Kivipelto Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe Neurology 74 2010 956 964
9. M. Simons, F. Schwarzler, D. Lutjohann Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial Ann Neurol 52 2002 346 350
10. M. Sano, K.L. Bell, D. Galasko A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease Neurology 77 2011 556 563
11. D.L. Sparks, D.J. Connor, M.N. Sabbagh Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial Acta Neurol Scand Suppl 185 2006 3 7
12. B. McGuinness, J. O'Hare, D. Craig, R. Bullock, R. Malouf, P. Passmore Cochrane review on 'Statins for the treatment of dementia' Int J Geriatr Psychiatry 2012 Apr 2 [Epub ahead of print]
13. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs http://www.fda.gov/Drugs/DrugSafety/ucm293101. htm Accessed April 20, 2012
14. L.R. Wagstaff, M.W. Mitton, B.M. Arvik, P.M. Doraiswamy Statin-associated memory loss: analysis of 60 case reports and review of the literature Pharmacotherapy 23 2003 871 880
15. K.P. Padala, P.R. Padala, J.F. Potter Statins: a case for drug withdrawal in patients with dementia J Am Geriatr Soc 58 2010 1214 1216
16. M.F. Muldoon, S.D. Barger, C.M. Ryan Effects of lovastatin on cognitive function and psychological well-being Am J Med 108 2000 538 546
17. M.F. Muldoon, C.M. Ryan, S.M. Sereika Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults Am J Med 117 2004 823 829
18. A. Algotsson, B. Winblad Patients with Alzheimer's disease may be particularly susceptible to adverse effects of statins Dement Geriatr Cogn Disord 17 2004 109 116
19. M.F. Folstein, S.E. Folstein, P.R. McHugh "Mini-mental state" A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 1975 189 198
20. M.N. Lopez, R.A. Charter, B. Mostafavi Psychometric properties of the Folstein Mini-Mental State Examination Assessment 12 2005 137 144
21. K.A. Welsh, N. Butters, R.C. Mohs The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Part V. A normative study of the neuropsychological battery Neurology 44 1994 609 614
22. S. Katz, A.B. Ford, R.W. Moskowitz Studies of illness in the aged The index of ADL: a standardized measure of biological and psychosocial function JAMA 185 1963 914 919
23. M.P. Lawton, E.M. Brody Assessment of older people: self-maintaining and instrumental activities of daily living Gerontologist 9 1969 179 186
24. A. Orsi, O. Sherman, Z. Woldeselassie Simvastatin-associated memory loss Pharmacotherapy 21 2001 767 769
25. D.L. Sparks, D.J. Connor, P.J. Browne HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier J Nutr Health Aging 6 2002 324 331
26. D.S. King, A.J. Wilburn, M.R. Wofford Cognitive impairment associated with atorvastatin and simvastatin Pharmacotherapy 23 2003 1663 1667
27. P.A. Kiener, P.M. Davis, J.L. Murray Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors Int Immunopharmacol 1 2001 105 118
28. M.A. Evans, B.A. Golomb Statin-associated adverse cognitive effects: survey results from 171 patients Pharmacotherapy 29 2009 800 811
29. Z.S. Nasreddine, N.A. Phillips, V. Bedirian The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment J Am Geriatr Soc 53 2005 695 699